Literature DB >> 3793270

Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3.

J M Esteban, D Colcher, P Sugarbaker, J A Carrasquillo, G Bryant, A Thor, J C Reynolds, S M Larson, J Schlom.   

Abstract

Monoclonal antibody (MAb) B72.3 has been previously shown, by in vitro assays, to have a high degree of specificity for carcinomas of the colon, ovary and breast versus normal adult tissues. B72.3 IgG was labelled with 131I and injected i.v. into 20 patients with known or suspected colorectal cancer. All patients subsequently underwent surgical exploration, with tumor and selected normal tissues removed for staging purposes. The selective localization of 131I-MAb B72.3 IgG was demonstrated in biodistribution studies in which the % ID/g of each tumor was compared with that of the normal tissues, thus providing a relative RI for each lesion. Of the tumor lesions, 70% (99/142) had an RI of at least 3 (i.e., 3 times greater uptake per gram than normal tissues), and 31% of the tumor lesions had RIs of over 10. Only 12 of 210 (6%) histologically normal tissues had RIs of greater than 3; either these tissues were adjacent to or draining tumor masses or, as in the case of 2 patients, the high RI values were apparently due to deposition of immune complexes in the splenic tissues. Several parameters were studied to determine factors that might influence MAb localization. Whereas tumors of all histologic types localized the MAb, 31% of the well-differentiated mucinous carcinomas displayed tumor-to-normal ratios greater than 10, while less than 5% of the lesions of other tumor types demonstrated similar localization. The expression of the antigen (TAG-72) detected by MAb B72.3 in these tumors, as studied by immunohistochemical techniques using tissue sections, did not always correlate with the outcome of the MAb distribution. No differences in MAb uptake were observed among the carcinoma lesions from numerous anatomic locations, demonstrating the ability of i.v. administered B72.3 to reach all the tumor sites. Furthermore, autoradiographic studies of tumors showed good penetration of the MAb into the medial areas of the tumors, regardless of their size.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3793270     DOI: 10.1002/ijc.2910390110

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

Review 1.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Genetic engineering of high affinity anti-human colorectal tumour mouse/human chimeric antibody.

Authors:  J Xiang; Z Chen
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

3.  Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes.

Authors:  M A Reddish; L Jackson; R R Koganty; D Qiu; W Hong; B M Longenecker
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

Review 4.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

5.  Concentration and distribution of tumor associated antigens TAG-72 and CEA in stomach cancer.

Authors:  J K Chung; M C Lee; H K Chung; S M Lim; J J Jang; C S Koh
Journal:  Ann Nucl Med       Date:  1995-02       Impact factor: 2.668

Review 6.  Redirection of cellular cytotoxicity. A two-step approach using recombinant single-chain Fv molecules.

Authors:  A J George; J A Titus; C R Jost; I Kurucz; P Perez; S M Andrew; P J Nicholls; J S Huston; D M Segal
Journal:  Cell Biophys       Date:  1995-06

7.  Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.

Authors:  F J Primus; T K Pendurthi; P Hutzell; S Kashmiri; D C Slavin; R Callahan; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72.

Authors:  K Irvine; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

9.  Production of a bifunctional hybrid molecule B72.3/metallothionein-1 by protein engineering.

Authors:  J Xiang; J Koropatnick; Y Qi; X Luo; T Moyana; K Li; Y Chen
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

10.  High-affinity chimeric anti-(colorectal carcinoma) antibody correlated to enhanced tumor targeting in biodistribution and imaging.

Authors:  Y Qi; G Matte; A Wilkinson; X Jim
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.